Vir Biotechnology Awarded U.S. Government Contract to Support Pandemic Preparedness for Influenza and Other Infectious Disease Threats
October 04, 2022 08:00 ET
|
Vir Biotechnology, Inc.
– First award from the agency’s solicitation for contracts for Pre-Exposure Prophylaxis for Influenza – – Initial investment of approximately $55 million from Biomedical Advanced Research and...
Global Respiratory Disease Testing Market Expected to Garner a Revenue of $20.1 Billion by 2027, despite COVID-19 Crisis | | Declared by Research Dive
September 14, 2022 09:02 ET
|
Research Dive
New York, USA, Sept. 14, 2022 (GLOBE NEWSWIRE) -- According to the report published by Research Dive, the global respiratory disease testing market is anticipated to generate a revenue of $20.1...
Dyadic Updates Market on Recent Scientific Achievements
September 13, 2022 08:00 ET
|
Dyadic International, Inc.
JUPITER, Fla., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Blue Water Vaccines to Present at The Universal Influenza Vaccines 2022 Conference in Oxford, United Kingdom
August 24, 2022 14:00 ET
|
Blue Water Vaccines Inc.
CINCINNATI, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”) a biopharmaceutical company developing transformational vaccines to address...
Blue Water Vaccines Announces Appointment of Retired Deloitte Consulting Senior Managing Director Simon Tarsh to Board of Directors
August 22, 2022 14:00 ET
|
Blue Water Vaccines Inc.
CINCINNATI, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”), a biopharmaceutical company developing transformational vaccines to address...
Blue Water Vaccines Reports Second Quarter 2022 Financial Results and Recent Business Highlights
August 15, 2022 16:00 ET
|
Blue Water Vaccines Inc.
Closed private placement in April 2022, with net proceeds of approximately $6.9 millionSigned multiple strategic agreements and collaborations to further vaccine candidate research, development, and...
Dyadic Reports Second Quarter 2022 Financial Results and Highlights Recent Company Developments
August 10, 2022 16:00 ET
|
Dyadic International, Inc.
Submission of a Clinical Trial Application (CTA) with South African Health Products Regulatory Authority (SAHPRA) to initiate a Phase 1 study to support clinical safety of proteins produced from...
Blue Water Vaccines Announces Signing of Sponsored Research Agreement with Cincinnati Children’s Hospital Medical Center for S&P Vaccine Platform Development
July 20, 2022 14:00 ET
|
Blue Water Vaccines Inc.
CINCINNATI, July 20, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”), a biopharmaceutical company developing transformational vaccines to address...
Global Adult Vaccines Market to Surpass US$ 29,025.87 Million by 2030, Says Coherent Market Insights (CMI)
July 12, 2022 08:40 ET
|
CMI
Seattle, July 12, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global adult vaccines market is estimated to be valued at US$ 16,790.11 million in 2022 and is expected to...
Dyadic to Participate in Bio-Manufacturing Innovation Summit and NIIMBL National Meeting
July 05, 2022 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., July 05, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and...